Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Renal Impact: Rivaroxaban Versus Vitamin K Antagonists in AF
Author(s): Phong Phan Dinh , Tri Huynh Quang Ho , Hung Manh Pham , et al Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
ERA 25: Switching from sMRAs to Finerenone
Author(s): Beatriz Fernandez Fernandez Added: 10 months ago
ERA 2025 - Real-world outcomes show switching from treatment with steroidal mineralocorticoid receptor antagonists (sMRAs) to finerenone is a safe option in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).Dr Beatriz Fernandez Fernandez (Hospital Universitario Fundación Jiménez Dïaz, Madrid, ES) joins us to discuss real-world outcomes from a study investigating the effect of… View more

Cardiovascular Renal Metabolic
ESC 23: MULTISTARS AMI Trial
Author(s): Linda Joosten Added: 2 years ago
ESC 2023 — Dr Linda Joosten (Julius Center for Health Sciences and Primary Care, NL) joins us to discuss the findings of the FRAIL-AF trial. FRAIL-AF is a multicentre, open-label randomised controlled clinical trial which studied frail elderly patients who receive vitamin K antagonist (VKA) treatment for atrial fibrillation (AF). Current clinical guidelines recommend non-vitamin K antagonists … View more

Anticoagulation

Demographic
EHRA 24: A Substudy of NOAH-AFNET 6
Author(s): Julius Nikorowitsch Added: 1 year ago
EHRA 24 - We are joined onsite by Dr Julius Nikorowitsch (University Heart and Vascular Centre Hamburg (UHZ), DE) to outline the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation in a substudy of the NOAH-AFNET 6 trial (NCT02618577).The substudy consisted of 2534 patients from… View more

Electrophysiology & Arrhythmia
Comparative Analysis of Direct Oral Anticoagulants in Atrial Fibrillation
Author(s): Ton Duy Mai , Tri Huynh Quang Ho , Sy Van Hoang , et al Added: 11 months ago

Anticoagulation

Electrophysiology & Arrhythmia
Factor XI Inhibition and AF
Author(s): Bianca Rocca , Hugo ten Cate Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
Research Area(s) / Expertise: Job title: Professor
Professor Keith AA Fox is Duke of Edinburgh Professor of Cardiology at the University of Edinburgh. Previous posts included Assistant Professor of Internal Medicine and Cardiology at Washington University School of Medicine, St Louis, USA; Senior Lecturer in Cardiology and Honorary Consultant Cardiologist at the University of Wales College of Medicine, Cardiff; Head of Division of Medical and… View more
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 5 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
Systematic Scoping on DOACS in NVAF Patients
Author(s): Shirley Siang Ning Tan , Wei Hong Lai , Lee Len Tiong , et al Added: 8 months ago

Anticoagulation

Electrophysiology & Arrhythmia
Author(s): Finn Gustafsson Added: 1 year ago
HFA 24 - Dr Finn Gustafsson (Rigshospitalet, DK) joined us onsite at the Heart Failure Association Congress to discuss the findings from a subanalysis of the ARIES HeartMate 3 study (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two… View more

Anticoagulation

Heart Failure